相关临床试验
0
0 进行中
药物批准
33
批准总数
监管机构
3
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Alfasigma S.p.A. has entered a share purchase agreement with SEVER Life Sciences B.V. to acquire 100% of Nordic Group B.V. and its subsidiaries. - The deal adds Nordic Pharma's rheumatoid arthritis business, led by the Nordimet® methotrexate franchise, to Alfasigma's rheumatology portfolio alongside Jyseleca®. - The acquisition deepens Alfasigma's commercial reach across 18 European countries and adds platforms in Canada and Japan, bringing 265 employees and approximately €190 million in 2025 revenue. - The transaction supports Alfasigma's M&A-led growth strategy focused on gastroenterology and immunology, subject to customary closing conditions and regulatory clearances.
• Nordic Pharma, a subsidiary of Nordic Group B.V., has partnered with Harrow to launch an authorized generic version of Maxitrol ophthalmic suspension for treating bacterial eye infections. • The new generic alternative enters a market where Maxitrol and its generic equivalents generated annual sales of $20.8 million in the U.S. as of January 2025, according to IQVIA data. • This product expansion strengthens Nordic Pharma's generic portfolio and aims to provide patients with a more affordable prescription option for treating ocular bacterial infections.
• Nordic Pharma has received CE Mark approval in the European Union for Lacrifill, a cross-linked hyaluronic acid gel that temporarily blocks tear drainage by occluding the canalicular system. • The innovative treatment offers a single in-office procedure with effects lasting up to 6 months, addressing a condition that affects approximately 30% of the European population. • Lacrifill, which previously received U.S. approval in June 2024, demonstrated promising results in a pilot study where 83% of participants experienced no pain and 63% reported improved eye comfort after treatment.
